Alkermes settles Lybalvi patent suit with Teva, licenses generic entry for 2039Nov 12PartnershipAlkermes, Inc.Minerva NeurosciencesUpdated
Alkermes posts Q3 2026 revenue of $480.1 million, touts orexin pipeline progressNov 3Quarterly updateAlkermes, Inc.
Alkermes registers expanded access program for pediatric LYBALVI patientsAug 4Trial updateAlkermes, Inc.olanzapine and samidorphan l-malate